Navigation Links
ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
Date:4/9/2008

zed cases of transmission of vCJD by transfusion of blood donated by persons incubating the disease. Transfusion transmission appears to be highly efficient in humans and animals. The 2006 National CJD Surveillance Unit report concluded that "the incidence of vCJD may increase again, particularly if different genetic subgroups are found but with longer incubation periods". Abnormal prion proteins are an essential component of vCJD infectivity and may be the only component. The adsorption of prion proteins by PRDT ligands removes vCJD infectivity.

For additional information please refer to the following articles:

------------------------------------------------------------------

Gregori L, Lambert BC, Gurgel P et al. Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligand. Transfusion 2006; 46:1152-1161

Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion : a case report. Lancet 2006; 368:2061-67

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Prometic to present at the American Chemical Society
2. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
3. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic provides business update - Over $35 million worth of business secured in January
6. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
7. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
8. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
9. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
10. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
11. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 Eisai Co., Ltd.,(Headquarters: Tokyo, President & ... of North America (Headquarters: New Jersey,the United States, ... in the schedule for submission to the U.S. ... Application (NDA) for E7389 (generic,name: eribulin mesylate) for ...
... 1 , - ENDORSE Global Findings Highlight ... VTE Management: Systematically Assess,Patient Risk for VTE and ... multinational study (Epidemiologic International Day for the,Evaluation of ... Acute,Hospital Care Setting) published today in the LANCET(1) ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced that ... community in New York City on Thursday, February 7,2008 ... be webcast live and available for replay on the,company,s ... CV Therapeutics, Inc., headquartered in Palo Alto, California, ...
Cached Biology Technology:Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 2Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 2The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 3The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis 4CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008 2
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... our cells migrate: nerve cells make their vital connections, ... organs, immune cells zero in to destroy pathogenic organisms, ... body. Scientists studying these migrations didn't know how cells ... Institute study has identified a fragment of a protein ...
... does matters after all. But for flying snakes, smaller ... In the May 15, 2005, issue of the Journal ... and behavior of flying snakes, and found that the ... of wing-like appendages, flying snakes are skilled aerial locomotors," ...
... Virginia Tech, has been awarded a Ralph E. Powe Junior ... his research on quorum sensing in bacteria. He is modeling ... by a bacteria colony once it has reached a critical ... to faculty members who are in the first two years ...
Cached Biology News:New understanding of cell movement may yield ways to brake cancer's spread 2Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Understanding how bacteria communicate may help scientists prevent disease 2Understanding how bacteria communicate may help scientists prevent disease 3
... a K-12 strain ideally suited as an ... transformation efficiency, blue/white screening capability (with appropriate ... in high yields of excellent quality plasmid ... potentially useful as a stringent host due ...
... Zealand White or Californian 8 - 10 ... 6 hours of collection, processed within 24 ... is then thawed in a cool waterbath, ... through a 0.22 micron filter, bottled, and ...
... Host Strain Competent Cell Sets Sets ... strain combinations The most common ... E. coli is to use chemically ... prepared in the laboratory, greater efficiency, reproducibility ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
Biology Products: